Wednesday, June 10, 2026

Patent intelligence Β· EP

EP 4732903

COKRISTALLE VON PITOLISTANTHYDROCHLORID

granted A61K 31/ 4453 A IA61P 25/ 00 A IA61P/2500
Status granted
Pipeline programs 6
Years to expiry 20
Applicant portfolio 9
Patent details β€” EP 4732903
Jurisdiction
EP
Status
granted
Grant date
Apr 29, 2026
Expiration
Apr 24, 2046
CPC classes
A61K 31/ 4453 A I, A61P 25/ 00 A I, A61P/2500
View on Google Patents β†—

Quick answer

EP 4732903 (COKRISTALLE VON PITOLISTANTHYDROCHLORID) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Apr 29, 2026. Expires Apr 24, 2046 (20 years remaining) β€” relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
β€”
CPC classes
A61K 31/ 4453 A I, A61P 25/ 00 A I, A61P/2500

More from BIOPROJET PHARMA [FR]

Related pharmaceutical patents in our USPTO index.

  1. EP 4681704

    NEUE FORMULIERUNGEN VON PITOLISANT

    BIOPROJET PHARMA [FR] Β· Expires Jan 16, 2046

    granted
  2. US 2025120959

    NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE

    BIOPROJET PHARMA [FR] Β· Expires Apr 12, 2045

    granted
  3. US 2024327366

    POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE

    BIOPROJET PHARMA [FR] Β· Expires Sep 28, 2044

    granted
  4. EP 3906927

    VERWENDUNG VON DOPAMIN-D3-TEILAGONISTEN ZUR BEHANDLUNG VON STΓ–RUNGEN DES ZENTRALEN NERVENSYSTEMS

    BIOPROJET PHARMA [FR] Β· Expires Nov 5, 2041

    granted
  5. US 2020024256

    TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

    BIOPROJET PHARMA [FR] Β· Expires Jan 18, 2040

    granted
  6. EP 3378477

    NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN

    BIOPROJET PHARMA [FR] Β· Expires Sep 21, 2038

    granted
  7. EP 2511275

    Neuartige Piperidinyl-monocarboxylsΓ€uren als S1P1 Rezeptoragonisten

    BIOPROJET SOC CIV [FR] Β· Expires Oct 12, 2032

    granted

Frequently asked questions

What is US patent 4732903?

EP 4732903 (COKRISTALLE VON PITOLISTANTHYDROCHLORID) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Apr 29, 2026. Expires Apr 24, 2046 (20 years remaining) β€” relevant for patent-cliff and LOE planning.

Who owns EP 4732903?

BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.

When does EP 4732903 expire?

Our index shows an expiration date of Apr 24, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.